KPHMW

Kiora Pharmaceuticals' S-3 shelf registration (File No. 333-295994) became effective on May 22…

The effective shelf creates a large overhang of up to ~11.8M shares relative to the current float. Monitor for any Form 4 filings or prospectus supplements indicating warrant exercises or share…

Kiora Pharmaceuticals reported a Q1 2026 net loss of $2.4M, wider than the $2.2M loss in Q1 2025…

Monitor upcoming safety reviews and data readouts from ABACUS-2 and KLARITY trials in H1 2027. The $5M equity raise provides near-term financial stability but dilutes existing shareholders.

Kiora Pharmaceuticals raised $15 million through a private placement of common stock and warrants…

The combination of a dilutive financing and key executive departure suggests underlying financial stress. The Perceptive Life Sciences investment indicates some institutional confidence, but traders…